Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 186Re-bivatuzumab in NSCLC
NCT02204059Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 1999
- Primary completion
- Feb 2001
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events, Number of patients with abnormal changes in laboratory parameters and 12 more. Started Dec 1999; status: completed.
02
Drugs
bivatuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02204059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204059.